Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PharmaCyte Biotech (PMCB) Non Operating Investment Income (2025 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Non Operating Investment Income for 2 consecutive years, with -$128939.0 as the latest value for Q1 2026.

  • Quarterly Non Operating Investment Income fell 277.52% to -$128939.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$300381.0 through Jan 2026, down 513.57% year-over-year, with the annual reading at $66316.0 for FY2025, N/A changed from the prior year.
  • Non Operating Investment Income for Q1 2026 was -$128939.0 at PharmaCyte Biotech, down from -$60663.0 in the prior quarter.
  • The five-year high for Non Operating Investment Income was $72632.0 in Q1 2025, with the low at -$128939.0 in Q1 2026.